Shandong Weigao Group Medical Polymer
Shandong Weigao Group Medical Polymer Company Limited is a Chinese medical device enterprise that develops, manufactures, and markets single-use medical consumables, orthopedic implants, and blood purification products. The company operates through four main business segments: Medical Device Products, Orthopedic Products, Interventional Products, and Blood Purification Products. Its principal revenue drivers consist of high-volume sales of infusion sets, syringes, orthopedic joint and spine implants, vascular stents, and hemodialysis equipment to hospitals and healthcare providers. Shandong Weigao Group holds a leading market position in the Chinese medical consumables and devices industry, servicing thousands of domestic hospitals through an extensive commercial network. The enterprise focuses on advancing R&D for high-end medical implants, expanding hemodialysis service centers, growing international medical export sales, and upgrading automated manufacturing standards. Shandong Weigao Group Medical Polymer Company Limited is headquartered in Weihai, Shandong Province, China, and its H shares are publicly listed and traded on the Hong Kong Stock Exchange.
11 of the funds FundTelligence covers report a position in Shandong Weigao Group Medical Polymer.
- Legal name
- Shandong Weigao Group Medical Polymer Co Ltd
- Sector
- Health Care
- Country
- China
- Funds holding it
- 11
Funds holding Shandong Weigao Group Medical Polymer
- Nordea Stable Emerging Markets — Nordea Funds · 0.48 % (full portfolio disclosed, July 2026)
- KLP AksjeFremvoksende Markeder Flerfaktor — KLP · 0.12 % (full portfolio disclosed, June 2026)
- Storebrand Emerging Markets Plus — Storebrand · 0.01 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.01 % (full portfolio disclosed, October 2026)
- Nordea Stabil Balanceret — Nordea Funds · 0.01 % (full portfolio disclosed, July 2026)
- Nordea Stable Return Fund — Nordea Funds · 0.01 % (full portfolio disclosed, July 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
- Handelsbanken Emerging Markets Index — Handelsbanken · 0.0 % (full portfolio disclosed, September 2026)
Showing the 8 largest of 11 funds holding it.